M+ CRPC and pre-chemotherapy hormonal manipulation: the 302 data
Speakers:
Andrew Loblaw, MD
Objectives
To Discuss and to learn the update of the 302 data that will be presented at the ESMO meeting.
To Discuss and to learn the added benefit of Zytiga in CRPC chemotherapy naive patients.
To Discuss and to learn the role of the raidation oncologist, the urologist, and the medical oncologist in the management of these patients.